Reasons why few patients with acute stroke receive tissue plasminogen activator

被引：94

作者：

Bambauer, Kara Z.

Johnston, S. Claiborne

Bambauer, Derek E.

Zivin, Justin A.

机构：

[1] Univ Calif San Diego, Dept Neurol, La Jolla, CA 92093 USA

[2] Harvard Univ, Sch Med, Dept Ambulatory & Care Prevent, Boston, MA USA

[3] Harvard Univ, Pilgrim Hlth Care, Boston, MA USA

[4] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

[5] Harvard Univ, Sch Med, Berkman Ctr Internet & Soc, Cambridge, MA 02138 USA

来源：

ARCHIVES OF NEUROLOGY | 2006年 / 63卷 / 05期

关键词：

D O I：

10.1001/archneur.63.5.661

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.

引用

页码：661 / 664

页数：4

共 31 条

[1] Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].

Albers, GW ;

Bates, VE ;

Clark, WM ;

Bell, R ;

Verro, P ;

Hamilton, SA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150

[2]

*AM AC NEUR, COD T PA INF REL PHY

[3]

*AM COLL EM PHYS, US INTR TPA MAN AC S

[4]

*AM STROK ASS, WHAT STROK

[5]

[Anonymous], 2004, PENN STATE LAW REV

[6] Acute stroke care in the US - Results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry [J].

Arora, S ;

Broderick, JP ;

Frankel, M ;

Heinrich, JP ;

Hickenbottom, S ;

Karp, H ;

LaBresh, KA ;

Malarcher, A ;

Mensah, G ;

Moomaw, CJ ;

Reeves, MJ ;

Schwamm, L ;

Weiss, P .

STROKE, 2005, 36 (06) :1232-1240

[7] Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility [J].

Barber, PA ;

Zhang, J ;

Demchuk, AM ;

Hill, MD ;

Buchan, AM .

NEUROLOGY, 2001, 56 (08) :1015-1020

[8] A systems approach to immediate evaluation and management of hyperacute stroke - Experience at eight centers and implications for community practice and patient care [J].

Brott, T ;

Broderick, J ;

Kothari, R ;

ODonoghue, M ;

Barsan, W ;

Tomsick, T ;

Spilker, J ;

Miller, R ;

Sauerbeck, L ;

Farrell, J ;

Kelly, J ;

Perkins, T ;

McDonald, T ;

Rorick, M ;

Hickey, C ;

Armitage, J ;

Perry, C ;

Thalinger, K ;

Rhude, R ;

Schill, J ;

Becker, PS ;

Heath, RS ;

Adams, D ;

Reed, R ;

Klei, M ;

Hughes, A ;

Anthony, J ;

Baudendistel, D ;

Zadicoff, C ;

Rymer, M ;

Bettinger, I ;

Laubinger, P ;

Schmerler, M ;

Meiros, G ;

Lyden, P ;

Dunford, J ;

Zivin, J ;

Rapp, K ;

Babcock, T ;

Daum, P ;

Persona, D ;

Brody, M ;

Jackson, C ;

Lewis, S ;

Liss, J ;

Mahdavi, Z ;

Rothrock, J ;

Tom, T ;

Zweifler, R ;

Kobayashi, J .

STROKE, 1997, 28 (08) :1530-1540

[9] Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke [J].

Brown, DL ;

Barsan, WG ;

Lisabeth, LD ;

Gallery, ME ;

Morgenstern, LB .

ANNALS OF EMERGENCY MEDICINE, 2005, 46 (01) :56-60

[10] Effectiveness of t-PA in acute ischemic stroke - Outcome relates to appropriateness [J].

Buchan, AM ;

Barber, PA ;

Newcommon, N ;

Karbalai, HG ;

Demchuk, AM ;

Hoyte, KM ;

Klein, GM ;

Feasby, TE .

NEUROLOGY, 2000, 54 (03) :679-684

← 1 2 3 4 →